Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer…
RVNC INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Revance Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK--(BUSINESS WIRE)--$RVNC #RVNC--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized…
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025 16:30 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025 16:30 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025 16:30 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…
Actimed Therapeutics appoints Dr Fabio Dorigotti as Chief Medical Officer to drive further pipeline development for cancer cachexia and other muscle wasting disorders
January 16, 2025 03:00 ET | Source: Actimed Therapeutics Fabio Dorigotti brings…
PulseSight Therapeutics announces the initiation of the clinical plan of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy
January 14, 2025 03:00 ET | Source: PulseSight Therapeutics S.A.S PARIS, Jan.…
Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease
Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease…
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025 17:00 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025 17:00 ET | Source: Xilio Therapeutics, Inc. WALTHAM, Mass.,…